Dasatinib metabolite M6 (Dasatinib carboxylic acid) is an oxidative metabolite of Dasatinib, a potent and orally active inhibitor of both Bcr-Abl and Src family tyrosine kinases[1].
AM-6761 is a potent inhibitor of the MDM2-p53 interaction. In the SJSA-1 osteosarcoma xenograft model, AM-6761 shows excellent antitumor activity with an ED50 of 11 mg kg.
AM6538 is a long-acting, high affinity, and pseudo-irreversible cannabinoid antagonist, structurally analogous to rimonabant. It serves as a valuable tool for assessing the apparent efficacy of cannabinoid partial and full agonists. Additionally, AM6538 holds potential for future investigations that necessitate temporary reductions in cannabinoid receptor availability[1].